<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02052336</url>
  </required_header>
  <id_info>
    <org_study_id>CJ_APA_103</org_study_id>
    <nct_id>NCT02052336</nct_id>
  </id_info>
  <brief_title>Drug-Drug Interaction Study Between CJ-12420 and Clarithromycin in Healthy Male Subjects</brief_title>
  <official_title>An Open-label, Randomized, 6-Sequence, 3-Period Crossover Study to Evaluate a Pharmacokinetic Drug Interaction Between CJ-12420 and Clarithromycin in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CJ HealthCare Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CJ HealthCare Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective: To assess the effect of the coadministration of multiple dose of CJ-12420
      and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.

      Secondary Objective(s): To assess the safety of the coadministration of multiple dose of
      CJ-12420 and clarithromycin in healthy subjects
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open-label, randomized, 6-sequence, 3-period, 3-treatment crossover design
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin</measure>
    <time_frame>Blood sampling during 12 or 24hrs after administration</time_frame>
    <description>Cmax, Cmin, Tmax, AUC(tau), CL/F, T1/2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The safety of the coadministration of multiple dose of CJ-12420 and clarithromycin in healthy subjects</measure>
    <time_frame>6 days after last visit</time_frame>
    <description>Safety and tolerability parameters will include laboratory (haematology, clinical chemistry, urinalysis, 12-lead ECG) values at Screening, Day-1 and Day 6 at each period and Follow-up.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>CJ-12420 200 mg + Clarithromycin 500mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CJ-12420 200mg QD for 5 days + Clarithromycin 500mg BID for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CJ-12420 200mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CJ-12420 200mg QD for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clarithromycin 500mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clarithromycin 500mg BID for 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CJ-12420 200mg + Clarithromycin 500mg</intervention_name>
    <description>To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.</description>
    <arm_group_label>CJ-12420 200mg</arm_group_label>
    <arm_group_label>Clarithromycin 500mg</arm_group_label>
    <other_name>CJ-12420 200mg for 5 days + Clarithromycin 500mg for 5 days</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CJ-12420 200mg</intervention_name>
    <description>To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.</description>
    <arm_group_label>CJ-12420 200 mg + Clarithromycin 500mg</arm_group_label>
    <arm_group_label>Clarithromycin 500mg</arm_group_label>
    <other_name>CJ-12420 200mg for 5 days</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin 500mg</intervention_name>
    <description>To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.</description>
    <arm_group_label>CJ-12420 200 mg + Clarithromycin 500mg</arm_group_label>
    <arm_group_label>CJ-12420 200mg</arm_group_label>
    <other_name>Clarithromycin 500mg for 5 days</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male volunteers in the age between 19 and 45 years old

          -  Body mass index(BMI) in the range of 19 to 28 kg/m2

          -  Understand the requirement of the study and voluntarily consent to paticipate in the
             study

        Exclusion Criteria:

          -  History of clinically significant medical history or disease (hepatic, kidney,
             gastrointestinal,respiratory, musculoskeletal, endocrine,neuro-psychiatric,
             haemato-oncologic,urinary tract, cardiac arrhythmia and cardiovascular system) judged
             by investigator.

          -  Clinically significant abnormal laboratory results within at least 28 days prior to
             the first day of drug administration. AST or ALT &gt; 1.25 times of upper limit value
             Total bilirubin &gt; 1.5 times of upper limit value estimated GFR :less than 80 mL/min

          -  Clinically significant abnormal ECG results within at least 28 days prior to the first
             day of drug administration PR ≥ 210 msec QRS ≥ 120 msec QT ≥ 500 msec QTcF ≥ 500 msec

          -  Clinically significant hypersensitivity reaction against investigational drug or other
             drugs

          -  history of drug abuse or &quot;positive&quot; results from drug screening test.

          -  Take medicine such as prescription medicine or herbal medicine, over-the-counter drug,
             vitamin supplements

          -  Person who have intake history of food or drug which can affect drug absorption, drug
             distribution, drug metabolism, and drug excretion and bowel activity

          -  Volunteer have a history of donation of whole blood donation, apheresis, transfusion

          -  Volunteer a heavy drinker(30g/day), smoker(10 cigarettes/day), heavy caffeine
             consumer(400mg/day)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Inje university college of medicine Busan Paik Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2014</study_first_submitted>
  <study_first_submitted_qc>January 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2014</study_first_posted>
  <last_update_submitted>December 13, 2016</last_update_submitted>
  <last_update_submitted_qc>December 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug-Drug interaction</keyword>
  <keyword>Pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clarithromycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

